×

Do you want to link to this External Site and leave Amgen.com?

YOU ARE NOW LEAVING AMGEN'S WEB SITE. Amgen takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site.

SEC Filings

Form 10-Q
AMGEN INC filed this Form 10-Q on 10/31/2018
Document Outline
Entire Document (7479.6 KB)
Subdocument 1 - 10-Q - 10-Q
Page 1 - UNITED STATES
Page 2 - AMGEN INC.
Page 3 - PART I FINANCIAL INFORMATION
Page 4 - AMGEN INC.
Page 5 - AMGEN INC.
Page 6 - AMGEN INC.
Page 7 - AMGEN INC.
Page 8 - Product sales and sales deductions
Page 9 - Other recent accounting pronouncements
Page 10 - 2. Restructuring
Page 11 - 4. Revenues
Page 12 - Financing and payment
Page 13 - 6. Earnings per share
Page 14 - 7. Collaborations
Page 15 - N/A
Page 16 - N/A
Page 17 - Equity securities
Page 18 - Other intangible assets
Page 19 - 11. Financing arrangements
Page 20 - 12. Stockholders equity
Page 21 - 13. Fair value measurement
Page 22 - N/A
Page 23 - Interest-bearing and equity securities
Page 24 - Derivatives
Page 25 - Summary of the fair values of other financial instruments
Page 26 - Fair value hedges
Page 27 - N/A
Page 28 - Derivatives not designated as hedges
Page 29 - 15. Contingencies and commitments
Page 30 - SensiparPediatric Exclusivity Litigation
Page 31 - RESULTS OF OPERATIONS
Page 32 - Inflammation
Page 33 - Results of operations
Page 34 - Neulasta
Page 35 - Aranesp
Page 36 - EPOGEN
Page 37 - Operating expenses
Page 38 - Nonoperating expense/income and income taxes
Page 39 - Financial condition, liquidity and capital resources
Page 40 - Global economic conditions may negatively affect us and may magnify certain risks that affect our bu
Page 41 - N/A
Page 42 - PART II OTHER INFORMATION
Page 43 - We currently face competition from biosimilars and expect to face increasing competition from biosim
Page 44 - We currently face competition from biosimilars and expect to face increasing competition from biosim
Page 45 - Our intellectual property positions may be challenged, invalidated or circumvented, or we may fail t
Page 46 - USE OF PROCEEDS
Page 47 - INDEX TO EXHIBITS
Page 48 - N/A
Page 49 - N/A
Page 50 - N/A
Page 51 - N/A
Page 52 - SIGNATURES
Subdocument 2 - EX-10.23 - AGREEMENT BETWEEN AMGEN INC. AND MR. MURDO GORDON
Page 1 - Exhibit 10.23
Page 2 - N/A
Page 3 - This offer of employment is contingent upon confirmation by Amgen of information listed on your empl
Page 4 - ATTACHMENT 1
Page 5 - NEW STAFF MEMBER LETTER AND CERTIFICATION
Page 6 - CERTIFICATION
Page 7 - AMGEN SIGN-ON/RETENTION BONUS AGREEMENT
Page 8 - AMGEN RELOCATION AGREEMENT
Subdocument 3 - EX-31 - RULE 13A-14(A) CERTIFICATIONS
Page 1 - Exhibit 31
Page 2 - CERTIFICATIONS
Subdocument 4 - EX-32 - SECTION 1350 CERTIFICATIONS
Page 1 - Exhibit 32
Page 2 - Certification of Chief Financial Officer
XBRL Item - EX-101.INS - XBRL INSTANCE DOCUMENT (What's this?)
XBRL Item - EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT (What's this?)
XBRL Item - EX-101.CAL - XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT (What's this?)
XBRL Item - EX-101.DEF - XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT (What's this?)
XBRL Item - EX-101.LAB - XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT (What's this?)
XBRL Item - EX-101.PRE - XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT (What's this?)
XBRL Viewer